FY2026 Earnings Estimate for argenx Issued By William Blair

argenx SE (NASDAQ:ARGX) – William Blair upped their FY2026 EPS estimates for argenx in a research report issued on Friday, February 28th. William Blair analyst M. Minter now anticipates that the company will post earnings of $26.61 per share for the year, up from their prior estimate of $26.08. William Blair has a “Outperform” rating on the stock. The consensus estimate for argenx’s current full-year earnings is $3.13 per share. William Blair also issued estimates for argenx’s FY2027 earnings at $28.62 EPS and FY2028 earnings at $40.92 EPS.

A number of other research firms have also commented on ARGX. Scotiabank raised argenx from a “sector perform” rating to a “sector outperform” rating and raised their price target for the stock from $439.00 to $715.00 in a research report on Tuesday, November 5th. Wells Fargo & Company raised their target price on shares of argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a report on Friday. JPMorgan Chase & Co. lifted their price target on shares of argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. Truist Financial reissued a “buy” rating and set a $700.00 price objective (up previously from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Finally, Evercore ISI raised their price objective on shares of argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. One analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $661.17.

argenx Trading Down 0.3 %

ARGX stock opened at $622.61 on Monday. argenx has a 1-year low of $349.86 and a 1-year high of $678.21. The firm has a market cap of $37.83 billion, a PE ratio of -707.51 and a beta of 0.58. The business’s 50-day moving average price is $642.62 and its two-hundred day moving average price is $591.22.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. GeoWealth Management LLC boosted its holdings in shares of argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock valued at $31,000 after buying an additional 18 shares during the last quarter. Steward Partners Investment Advisory LLC raised its position in argenx by 5.6% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock worth $234,000 after acquiring an additional 20 shares in the last quarter. SG Americas Securities LLC raised its position in argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after acquiring an additional 21 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in argenx by 38.2% in the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after acquiring an additional 21 shares during the last quarter. Finally, Dynasty Wealth Management LLC grew its position in shares of argenx by 3.4% in the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock valued at $416,000 after acquiring an additional 22 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.